Literature DB >> 12772498

Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy.

Naruya Tomita1, Tetsuya Tomita, Kazuhiko Yuyama, Takahiro Tougan, Tsuyoshi Tajima, Toshio Ogihara, Ryuichi Morishita.   

Abstract

The inhibition of specific transcription regulatory proteins is a novel approach to regulate gene expression. The transcriptional activities of DNA binding proteins can be inhibited by the use of double-stranded oligonucleotides (ODNs) that compete for binding to their specific target sequences in promoters and enhancers. Transfection of this cis-element double-stranded ODN, referred to as decoy ODN, has been reported to be a powerful tool that provides a new class of anti-gene strategies to gene therapy and permits examination of specific gene regulation. We have demonstrated the usefulness of this decoy ODN strategy in animal models of restenosis, myocardial infarction, glomerulonephritis and rheumatoid arthritis. However, one of the major limitations of decoy ODN technology is the rapid degradation of phosphodiester ODNs by intracellular nucleases. To date, several different types of double-stranded decoy ODNs have been developed to overcome this issue. Circular dumb-bell (CD) double-stranded decoy ODNs that were developed to resolve this issue have attracted a high level of interest. In this review, the applications of decoy ODN strategy and the advantages of modified CD double-stranded decoy ODNs will be discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772498

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  5 in total

Review 1.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

2.  Regulation of transcription through light-activation and light-deactivation of triplex-forming oligonucleotides in mammalian cells.

Authors:  Jeane M Govan; Rajendra Uprety; James Hemphill; Mark O Lively; Alexander Deiters
Journal:  ACS Chem Biol       Date:  2012-05-11       Impact factor: 5.100

Review 3.  Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.

Authors:  Maryam Mahjoubin-Tehran; Yong Teng; Amin Jalili; Seyed Hamid Aghaee-Bakhtiari; Alexander M Markin; Amirhossein Sahebkar
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

4.  Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo.

Authors:  Yasuo Kunugiza; Tetsuya Tomita; Naruya Tomita; Ryuichi Morishita; Hideki Yoshikawa
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 5.  How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development.

Authors:  Qiongyu Duan; Tianyu Hu; Qiuxia Zhu; Xueying Jin; Feng Chi; Xiaodong Chen
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.